- alle zwei WochenErscheinungsrhythmus
- 1 h 08typische Länge
- vor 12 Std.letzte Folge
Folgenzu den neuesten
Ep153: Rick Young on Studying Gene Expression for Drug Discovery
Rick Young, professor at MIT and co-founder of Syros Pharmaceuticals, CAMP4 Therapeutics, Omega Therapeutics, and Dewpoint Therapeutics, on studying gene expression for drug discovery.
Ep152: Jens Eckstein on Investing in Healthy Aging
Jens Eckstein, investment partner at Hevolution Foundation, on investing in healthy aging.
Ep151: Shelley Force Aldred and Nathan Trinklein on Bispecific Antibodies for Cancer
Shelley Force Aldred and Nathan Trinklein, co-founders of Rondo Therapeutics, on the opportunity with bispecific antibodies for cancer.
Ep150: Jeff Jonker on the Small Molecule Drug Discovery Renaissance
Jeff Jonker, CEO of San Diego-based Belharra Therapeutics, on the renaissance in small molecule drug discovery.
Ep149: Nancy Stagliano on Precision Neuroscience
Nancy Stagliano, CEO of South San Francisco-based Neuron23, on bringing precision medicine to neuroscience drug discovery.
Ep148: Diana Brainard on the Fight Against Infectious Disease
Diana Brainard, CEO of AlloVir, on leading the fight against infectious diseases.
Ep147: Reid Huber on Investing in the Future of Medicine
Reid Huber, partner at Third Rock Ventures, on investing in the future of medicine.
Ep146: Jeff Huber on Life in Tech and Biotech
Jeff Huber, co-founder and general partner at Triatomic Capital, on his career path in tech, and then biotech.
Ep145: Lori Lyons-Williams on Targeted Radiopharmaceuticals for Cancer
Lori Lyons-Williams, CEO of Abdera Therapeutics, on developing targeted radiopharmaceuticals for cancer.
Ep143: Zach Weinberg and Alexis Borisy on Freeing the Biotech Founders
Zach Weinberg and Alexis Borisy of Curie.Bio on Freeing the Biotech Founders
Ep142: Fred Appelbaum on how 'Living Medicine' Came to Be
Fred Appelbaum, a physician, scientist and leader at the Fred Hutchinson Cancer Center, on 'Living Medicine,' his new book about the development of bone marrow transplantation and the rise of cell therapy.
Ep141: Colin Hill on Digging Deep into Data, Finding New Drug Targets
Colin Hill, co-founder and CEO of Aitia, on digging deep into biological datasets and finding new drug targets.
Ep140: Yung Lie on Supporting Young Scientists with Bold, Brave Ideas
Yung Lie, president and CEO of Damon Runyon Cancer Research Foundation, on advancing cancer research by supporting young scientists with bold and brave ideas.
Ep139: Kevin Conroy on Early Detection of Cancer
Kevin Conroy, CEO of Exact Sciences, on early detection of cancer.
Ep138: Jodie Morrison on Becoming a Biotech CEO
Jodie Morrison, acting CEO of Q32Bio, on becoming a biotech CEO.
Ep137: Aaron Ring on Immunotherapy for Cancer & More
Aaron Ring, a scientist at Yale moving to the Fred Hutchinson Cancer Center, on applying immunology and protein engineering for cancer therapy and more.
Ep136: Deborah Palestrant on Building Biotech Startups
Deborah Palestrant, partner at 5AM Ventures and head of the 4:59 initiative, on building biotech startups.
Ep135: John Maraganore on Developing a New Class of Medicines
John Maraganore, former founding CEO of Alnylam Pharmaceuticals, on his life in biotech and developing RNA interference as a new class of medicine.
Ep134: Emile Nuwaysir on In Vivo Gene Editing Therapies
Emile Nuwaysir, CEO of Boston-based Ensoma, on developing off-the-shelf in vivo gene editing therapies.
Ep133: Catherine Stehman-Breen on Epigenetic Editing Therapies
Catherine Stehman-Breen, CEO of Boston-based Chroma Medicine, on developing epigenetic editing therapies.
Ep132: Eric Dobmeier on Treating Kidney Disease
Eric Dobmeier, CEO of Seattle-based Chinook Therapeutics, on new strategies for treating kidney diseases.
Ep131: Ryan Watts on Neuroscience Drug R&D
Ryan Watts, CEO of South San Francisco-based Denali Therapeutics, on neuroscience drug discovery and development.
Ep130: David Hallal on a Life in Biotech & the Cell Therapy Wave
David Hallal, CEO of ElevateBio, on a long career in biotech and the coming 50-year opportunity in cell therapy and gene therapy.
Ep129: Joanne Smith-Farrell on Engineered B-Cell Therapies
Joanne Smith-Farrell, CEO of Cambridge, Mass.-based Be Biopharma, on Engineered B-Cell Therapies for Cancer & Rare Diseases.
Ep128: Rick Berke on Building a Biotech Journalism Outlet to Last
Rick Berke, co-founder and executive editor of STAT, on building a biotech journalism outlet to last.
Ep127: Jeb Keiper on Computational Drug Discovery
Jeb Keiper, CEO of Nimbus Therapeutics, on computational drug discovery, an unusual business model, and an important new Tyk2 inhibitor for psoriasis and other forms of autoimmunity.
Ep126: DA Wallach on Becoming a Biotech VC
DA Wallach, founder and general partner of TIME Bioventures, on becoming a biotech venture investor.
Ep125: Barry Greene on a New Drug for Depression
Barry Greene, CEO of Cambridge, Mass.-based Sage Therapeutics, on plans to introduce a new type of treatment for depression and postpartum depression.
Ep124: Shehnaaz Suliman on Delivery of Genetic Medicines
Shehnaaz Suliman, CEO of ReCode Therapeutics, on lipid nanoparticle delivery of genetic medicines.
